

# Serum Adiponectin, Leptin, C-Peptide, Homocysteine, and Colorectal Adenoma Recurrence in the Polyp Prevention Trial

Gerd Bobe<sup>1</sup>, Gwen Murphy<sup>3</sup>, Connie J. Rogers<sup>2</sup>, Kenneth W. Hance<sup>2</sup>, Paul S. Albert<sup>5</sup>, Adeyinka O. Laiyemo<sup>6</sup>, Leah B. Sansbury<sup>7</sup>, Elaine Lanza<sup>1</sup>, Arthur Schatzkin<sup>4</sup>, and Amanda J. Cross<sup>4</sup>

## Abstract

**Background:** Serum adiponectin, leptin, C-peptide, and homocysteine are indicators for obesity, hyperinsulinemia, and chronic inflammation, which have all been associated with colorectal cancer.

**Aims:** To determine whether serum adiponectin, leptin, C-peptide, and homocysteine are associated with fat, fiber, fruit and vegetable, flavonol, or dry bean intake and colorectal adenoma recurrence.

**Methods:** Using logistic regression, we estimated odds ratios (OR) and 95% confidence intervals (95% CI) for adenoma recurrence in 627 participants from the control arm of the Polyp Prevention Trial, a 4-year trial that examined the effectiveness of a low-fat, high-fiber, high-fruit and vegetable diet on adenoma recurrence.

**Results:** Serum concentrations of C-peptide and homocysteine were inversely related to fiber, fruit and vegetable, and flavonol intake and positively related to percentage of calories from fat (all  $P_{\text{trend}} \leq 0.01$ ). High homocysteine concentrations were associated with any (4th versus 1st quartile: OR, 2.26; 95% CI, 1.30-3.94) and more than one adenoma recurrence (OR, 2.11; 95% CI, 1.01-4.40). Individuals in the highest, versus lowest, tertile of serum leptin concentration had a decreased risk of advanced adenoma recurrence (OR, 0.22; 95% CI, 0.06-0.79).

**Conclusion:** Our results suggest that serum homocysteine may serve as an indicator of dietary exposure, including a low-fat and high-fiber, high-fruit and vegetable, and high-flavonol diet, as well as colorectal adenoma recurrence.

**Impact:** Discovering biomarkers that are both modifiable and can predict cancer risk is critical. We identified serum homocysteine as a novel indicator that is modified by diet and predicts risk of adenoma recurrence. *Cancer Epidemiol Biomarkers Prev*; 19(6); 1441-52. ©2010 AACR.

## Introduction

Epidemiologic studies have recognized obesity as a risk factor for colorectal adenomas (1) and cancer (2, 3). Proteins that are secreted by adipocytes provide a plausible link between obesity and colorectal cancer. Two of those proteins, adiponectin and leptin, can alter the risk of cancer either directly by activating signal transduction pathways involved in carcinogenesis or indirectly by acting on insulin sensitivity and the inflammatory response

(4-6). Hyperinsulinemia or insulin resistance is directly related to excess adipose tissue (7).

Serum concentrations of adiponectin have been inversely associated with colorectal adenoma (8-10) and cancer (11, 12), but not in all (13, 14) studies. The data for leptin are inconsistent, with some studies finding a positive association for colorectal adenoma (15) and cancer (16-18) and others an inverse association for colorectal adenoma (8) and cancer (8, 19-21). C-peptide is an inactive by-product and marker of insulin production (22) and has been positively associated with colorectal cancer (23-25); in contrast, the evidence for a positive association with colorectal adenoma is limited to one (26) of the three (27, 28) studies conducted. Circulating homocysteine has been positively associated with hyperinsulinemia (29), and this highly reactive metabolite can promote inflammation, tissue damage, cardiovascular disease, and carcinogenesis (30, 31). Some studies observed a positive association between circulating homocysteine and colorectal adenoma (32) and adenoma recurrence (33), whereas others found no association between homocysteine and risk of colorectal adenoma (34-36).

In the Polyp Prevention Trial (PPT), participants that consumed a low-fat, high-fiber, high-fruit and vegetable

**Authors' Affiliations:** <sup>1</sup>Laboratory of Cancer Prevention and <sup>2</sup>Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute (NCI), NIH, Department of Health and Human Services (DHHS); <sup>3</sup>Infection and Immunoepidemiology Branch and <sup>4</sup>Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS; <sup>5</sup>Bioinformatics and Bioinformatics Branch, National Institute of Child Health and Human Development, NIH, DHHS; <sup>6</sup>Biometry Research Group, Division of Cancer Prevention, NCI, NIH, DHHS; and <sup>7</sup>Epidemiology and Genetics Research Program, Division of Cancer Control and Population Science, NCI, NIH, DHHS, Bethesda, Maryland

**Note:** G. Bobe and G. Murphy contributed equally to this work.

**Corresponding Author:** Gerd Bobe, 112 Withycombe Hall, Oregon State University, Corvallis, OR 97331. Phone: 541-737-1898; Fax: 541-737-4174. E-mail: gerd.bobe@oregonstate.edu

doi: 10.1158/1055-9965.EPI-09-1082

©2010 American Association for Cancer Research.

diet and, more specifically, a diet high in flavonols and dry beans had a decreased risk of advanced adenoma recurrence (37-39); however, participants in the intervention and control arm did not differ in adenoma recurrence (40). The aim of this study was to determine whether serum concentrations of adiponectin, leptin, C-peptide, and homocysteine were associated with diet and adenoma recurrence.

## Subjects and Methods

### Study population

Participants were from the PPT, a large 4-year multicenter, randomized, controlled trial to evaluate the effects of promoting a low-fat, high-fiber, and high-fruit and vegetable diet on the recurrence of colorectal adenomas. The study was approved by the institutional review boards of the National Cancer Institute and those of the collaborating centers. All subjects provided written informed consent. A detailed description of the study has been published elsewhere (40, 41). Briefly, men and women, ages 35 years or older, with at least one histologically confirmed colorectal adenoma removed in the prior 6 months, were randomized at baseline (T0) to the dietary intervention group or control group for 4 consecutive years of follow-up (T1, T2, T3, and T4). To be eligible, potential participants must not have had prior surgically resected adenomas or diagnoses of colorectal cancer, inflammatory bowel disease, or a polyposis syndrome and they had to be no more than 150% of their recommended body weight. In addition, participants could not be using lipid-lowering drugs or have medical conditions or dietary restrictions that would limit their compliance with the protocol.

A total of 2,079 participants were enrolled in the trial; 1,037 were randomized to the intervention arm and 1,042 to the control arm. At baseline and at each of the four annual follow-up visits, participants completed an interviewer-administered questionnaire about demographics, family history, and use of medication or supplements. In addition, participants completed a self-administered, validated, modified Block-National Cancer Institute food frequency questionnaire (41), which asked about the frequency of intake and portion size of 119 food and beverage items during the past year. Trained, certified nutritionists reviewed all food frequency questionnaires with participants. Flavonol intake was estimated based on 55 food and beverage items using the 2007 U.S. Department of Agriculture flavonoid database (42) and was calculated as the sum of isorhamnetin, kaempferol, myricetin, and quercetin (38). Dry bean intake was estimated based on a single question that asked about the intake of cooked dry beans such as pinto, navy beans, lentils, and bean soup (37). Compared with 24-hour dietary recall and 4-day food record data, the food frequency questionnaire slightly overestimated fat intake and underestimated fiber and fruit and vegetable intake and

had acceptable correlations of fat ( $r = 0.63$ ), fiber ( $r = 0.63$ ), fruit and vegetable ( $r = 0.72$ ), dry bean ( $r = 0.76$ ), and other macro- and micro-nutrients (41, 43).

Four years after randomization, 1,905 (91.6%) participants (958 in the intervention group and 947 in the control group) completed the study and underwent colonoscopy at T4. All lesions were examined for histologic features and degree of atypia by two independent pathologists. Recurrence outcomes were defined as having any, multiple ( $\geq 2$ ), advanced ( $\geq 1$  adenoma of  $\geq 1$  cm in size, having  $\geq 25\%$  villous component, or exhibiting high-grade dysplasia), or high-risk ( $\geq 1$  advanced adenoma or  $\geq 3$  adenomas) adenoma recurrence, relative to no polyp recurrence. This study only included participants in the control arm of the PPT that had serum samples, dietary exposure data from T1, and a final colonoscopy ( $n = 627$ ). For the analysis of adenoma recurrence, data from 108 individuals with nonadenomatous polyps only were excluded, which left data from 519 participants.

### Serum assays

At the baseline visit and at each of the four subsequent annual visits, participants were weighed and provided a venous blood sample after an overnight fast. Serum samples were stored at  $-70^{\circ}\text{C}$ . Samples taken at T1 were used for adiponectin, leptin, C-peptide, and homocysteine analyses; in addition, blood samples taken at T4 were used to measure serum concentrations of adiponectin and leptin. Because we were primarily interested in proteins secreted by adipocytes, we did not measure C-peptide and homocysteine at T4. Serum concentrations of adiponectin and leptin were determined at Pierce Biotechnology, using multiplex 96-well immune-chemiluminescent SearchLight Proteome Arrays and a SearchLight Imaging System. Bound adiponectin and leptin were detected with a biotinylated detection antibody, followed by the addition of streptavidin-horseradish peroxidase and, lastly, a patented chemiluminescent substrate (patent no. 6432662).

Serum concentrations of C-peptide and homocysteine were measured at the Department of Laboratory Medicine, Harvard Medical School (Boston, MA). C-peptide was measured by a competitive electrochemiluminescence immunoassay on the 2010 Elecsys autoanalyzer (Roche Diagnostics). The concentration of total homocysteine was determined using an enzymatic assay on a Hitachi 917 analyzer (Roche Diagnostics) using reagents and calibrators from Catch, Inc. The assay measures the formation of NAD from NADH, which is proportional to the amount of homocysteine in the sample. Adiponectin, C-peptide, and homocysteine were measured in duplicate and leptin in quadruplicate. Three standard assay controls that covered a range of concentrations and one pooled NIH serum sample were run on each plate as repeated duplicate measures and had interassay coefficients of variation (CV) of 39.9%, 13.2%, 5.0%, and 5.3% for adiponectin, leptin, C-peptide, and homocysteine, respectively. The high adiponectin CV was caused by day-to-day variation of the adiponectin values of the pooled

**Table 1.** Participant characteristics for the control arm of the PPT at T1, by adenoma recurrence at T4

T1 characteristics*	No polyp	Any adenoma		Multiple adenoma		High-risk adenoma		Advanced adenoma	
				<i>P</i> †		<i>P</i> †		<i>P</i> †	
Sample size	277	242		102		68		33	
Sex (% male)	53	72	<0.0001	73	0.0006	76	0.0005	73	0.04
Race (% Caucasian)	93	91	0.42	97	0.21	97	0.39	94	1.00
Education (% ≤high school)	25	24	0.84	25	1.00	26	0.88	27	0.83
Family history of colorectal cancer‡ (% yes)	29	29	0.92	28	1.00	29	0.88	33	0.55
Smoker (% current)	9	12	0.32	16	0.10	12	0.51	12	0.54
NSAID use‡ (% yes)	41	35	0.15	36	0.48	35	0.49	27	0.19
Supplement use‡ (% yes)	50	36	0.003	39	0.08	37	0.06	36	0.20
Hormone therapy‡ (% yes)	17	9	0.007	9	0.05	7	0.04	3	0.04
Age (y)	64.0 (56.0-70.0)	64.0 (57.0-71.0)	0.21	67.0 (61.0-73.0)	0.001	67.0 (62.0-73.0)	0.0006	67.0 (62.0-74.0)	0.02
BMI (kg/m <sup>2</sup> )	27.1 (24.7-29.8)	26.9 (25.1-30.8)	0.41	26.9 (25.0-31.2)	0.37	26.7 (25.0-31.0)	0.73	26.0 (24.7-29.0)	0.34
Physical activity‡ (h/wk)	6.83 (3.32-11.7)	6.89 (3.65-12.9)	0.34	5.67 (2.85-11.3)	0.35	7.26 (4.44-14.8)	0.20	9.05 (5.48-16.0)	0.06
Alcohol intake (g/d)	0.61 (0.00-9.30)	1.63 (0.00-11.6)	0.13	1.16 (0.00-9.30)	0.43	0.61 (0.00-6.02)	0.51	0.61 (0.00-9.15)	0.84
Energy intake (1,000 kcal/d)	1.74 (1.39-2.10)	1.82 (1.48-2.17)	0.13	1.80 (1.45-2.14)	0.57	1.82 (1.44-2.11)	0.59	1.84 (1.35-2.09)	0.67
Fat intake (% kcal/d)	33.5 (28.3-39.8)	34.3 (28.0-38.2)	0.67	33.8 (28.3-38.2)	0.50	34.0 (28.2-39.2)	0.91	33.8 (26.4-38.7)	0.64
Fiber intake (g/1,000 kcal/d)	9.72 (7.68-12.7)	9.55 (7.20-12.2)	0.49	10.1 (7.14-12.4)	0.99	10.3 (7.11-13.0)	0.89	9.40 (7.09-13.6)	0.82
Fruit and vegetable intake (servings/1,000 kcal/d)	2.14 (1.49-2.76)	2.02 (1.44-2.62)	0.35	2.14 (1.49-2.85)	0.63	2.06 (1.40-2.92)	0.92	2.04 (1.40-3.16)	0.90
Flavonol intake (mg/1,000 kcal/d)	8.59 (6.15-12.7)	8.61 (5.78-12.3)	0.49	8.16 (5.67-12.0)	0.35	8.19 (5.55-11.0)	0.15	9.48 (7.42-12.6)	0.66
Dry bean intake (g/1,000 kcal/d)	3.85 (1.55-7.72)	3.68 (1.50-7.41)	0.90	3.65 (1.30-7.90)	0.97	3.48 (1.18-6.19)	0.36	4.67 (2.51-9.34)	0.24

NOTE: Of the 627 participants, 108 with nonadenomatous polyps only were excluded from the analysis. Advanced adenoma is defined as ≥1 adenoma of ≥1 cm in size, having ≥25% villous component, or exhibiting high-grade dysplasia. High-risk adenoma is defined as ≥1 advanced adenoma or ≥3 adenomas.

\*Results presented as percent for categorical variables and as medians and interquartile ranges for continuous variables.

†All comparisons against the no-polyp group. *P* values for differences in proportions were calculated using Fisher's exact test. *P* values for differences in medians were calculated using Wilcoxon rank-sum test.

‡Family history of colorectal cancer was defined as having ≥1 first-degree relative with colorectal cancer at baseline. Physical activity was defined as self-reported time typically spent for any type of moderate or vigorous physical activity. Regular dietary supplement use was defined as taking supplement ≥1 weekly. Regular medication use, including NSAIDs, was defined as taking medication ≥1 monthly. Hormone replacement therapy included both unopposed estrogen and estrogen/progestin combinations.

**Table 2.** Medians (interquartile ranges) of serum adiponectin, leptin, C-peptide, and homocysteine concentrations at T1, by characteristics of participants at T1 in the control arm of the PPT (*n* = 627)

T1 characteristics	<i>n</i>	Adiponectin (ng/mL)		<i>n</i>	Leptin (ng/mL)		<i>n</i>	C-peptide (ng/mL)		<i>n</i>	Homocysteine (μmol/L)	
		Median (IQR)	<i>P</i> *		Median (IQR)	<i>P</i> *		Median (IQR)	<i>P</i> *		Median (IQR)	<i>P</i> *
Total	627	3.16 (1.94-5.10)		627	9.31 (4.63-17.4)		623	1.37 (0.98-1.80)		625	13.0 (10.8-15.7)	
Sex												
Female	243	3.48 (2.19-6.03)		243	19.3 (10.4-21.2)		241	1.20 (0.90-1.64)		242	11.5 (9.86-14.0)	
Male	384	3.01 (1.80-4.67)	0.004	384	6.31 (3.40-10.5)	<0.0001	382	1.45 (1.09-1.90)	<0.0001	383	13.9 (11.8-16.4)	<0.0001
Age quartiles (y)												
Q1 (36-56)	174	3.02 (1.56-4.51)		174	7.41 (4.23-18.9)		174	1.20 (0.92-1.69)		174	11.9 (10.3-14.7)	
Q2 (57-64)	160	3.16 (1.77-5.09)		160	9.02 (5.04-17.1)		159	1.41 (0.98-1.89)		159	13.3 (10.9-15.8)	
Q3 (65-70)	139	2.99 (2.06-5.08)		139	9.91 (5.75-17.8)		138	1.42 (1.13-1.89)		138	14.1 (11.5-16.1)	
Q4 (71-87)	154	3.58 (2.29-5.82)	0.04	154	9.40 (4.04-17.2)	0.64	152	1.38 (1.04-1.78)	0.01	154	13.3 (11.2-16.0)	0.0004
BMI (kg/m <sup>2</sup> )												
<25	158	3.37 (2.15-6.33)		158	5.58 (2.45-10.4)		157	0.98 (0.78-1.25)		157	12.0 (10.3-15.1)	
25-29.9	320	3.10 (1.87-4.99)		320	8.15 (4.88-17.0)		318	1.41 (1.08-1.81)		319	13.3 (10.9-16.0)	
≥30	149	3.03 (1.80-4.84)	0.11	149	15.6 (9.91-28.4)	<0.0001	148	1.69 (1.32-2.06)	<0.0001	149	13.6 (11.5-15.4)	0.003
Physical activity quartiles (h/wk) <sup>†</sup>												
Q1 (0-3.3)	156	3.16 (1.93-4.75)		156	14.4 (6.82-25.6)		154	1.50 (1.14-2.01)		156	13.2 (11.0-16.1)	
Q2 (3.4-6.7)	156	3.19 (1.96-5.09)		156	9.26 (4.88-18.2)		155	1.37 (0.96-1.74)		155	12.8 (10.8-15.2)	
Q3 (6.8-12.0)	156	3.01 (1.75-4.77)		156	9.35 (4.38-15.7)		156	1.27 (0.96-1.68)		156	12.2 (10.3-15.5)	
Q4 (12.1-91.2)	156	3.39 (2.06-5.84)	0.18	156	6.60 (3.46-11.8)	<0.0001	155	1.34 (0.89-1.74)	0.0005	155	13.6 (11.4-15.8)	0.12
Race												
Caucasian	576	3.21 (1.96-5.14)		576	9.14 (4.68-17.2)		572	1.37 (0.99-1.79)		574	13.0 (10.8-15.7)	
Other	51	2.68 (1.78-3.60)	0.04	51	10.7 (4.17-20.7)	0.45	51	1.41 (0.90-1.90)	0.94	51	12.9 (10.9-15.9)	0.91
NSAID use <sup>‡</sup>												
No	389	3.16 (1.86-5.08)		389	8.59 (4.70-17.0)		388	1.37 (0.98-1.83)		388	13.0 (10.9-15.7)	
Yes	235	3.21 (2.07-5.12)	0.75	235	9.76 (4.53-19.8)	0.34	232	1.38 (0.98-1.74)	0.73	234	13.0 (10.7-15.6)	0.73
Dietary intake												
Fat (% kcal)												
Q1 (15.2-28.3)	158	3.37 (2.10-5.83)		158	7.41 (3.88-15.8)		157	1.26 (0.98-1.67)		157	12.7 (10.4-15.4)	
Q2 (28.4-34.1)	155	2.84 (1.56-4.98)		155	10.5 (4.48-19.0)		153	1.29 (0.90-1.73)		154	12.6 (10.5-15.3)	
Q3 (34.2-39.3)	157	3.13 (1.85-4.84)		157	8.43 (5.18-17.8)		156	1.42 (1.09-1.81)		157	13.2 (11.2-15.6)	
Q4 (39.4-54.8)	156	3.12 (2.08-4.91)	0.14	156	10.0 (4.94-18.0)	0.05	156	1.44 (1.09-1.95)	0.0008	156	13.5 (11.2-16.1)	0.01
Fiber (g/1,000 kcal)												
Q1 (2.21-7.34)	157	3.02 (2.02-4.60)		157	9.06 (3.98-15.1)		157	1.44 (1.08-1.97)		157	13.9 (12.0-17.1)	
Q2 (7.35-9.55)	156	3.35 (2.26-4.95)		156	10.2 (5.32-21.9)		155	1.41 (1.01-1.77)		156	12.9 (10.9-15.2)	
Q3 (9.56-12.5)	157	3.00 (1.76-5.34)		157	9.05 (5.18-17.3)		157	1.28 (0.93-1.73)		157	12.5 (10.6-14.9)	

(Continued on the following page)

**Table 2.** Medians (interquartile ranges) of serum adiponectin, leptin, C-peptide, and homocysteine concentrations at T1, by characteristics of participants at T1 in the control arm of the PPT (*n* = 627) (Cont'd)

T1 characteristics	<i>n</i>	Adiponectin (ng/mL)		<i>n</i>	Leptin (ng/mL)		<i>n</i>	C-peptide (ng/mL)		<i>n</i>	Homocysteine (μmol/L)	
		Median (IQR)	<i>P</i> *		Median (IQR)	<i>P</i> *		Median (IQR)	<i>P</i> *		Median (IQR)	<i>P</i> *
Q4 (12.6-28.5)	156	3.28 (1.77-5.98)	0.66	156	7.63 (4.18-15.9)	0.02	153	1.27 (0.94-1.70)	0.003	154	12.6 (10.3-15.4)	0.009
Fruits and vegetables (servings/1,000 kcal)												
Q1 (0.33-1.45)	157	3.17 (1.99-4.68)		157	8.17 (4.02-14.7)		156	1.45 (1.12-1.96)		157	13.9 (11.8-16.4)	
Q2 (1.46-2.05)	156	3.08 (2.02-5.04)		156	7.61 (3.84-16.4)		156	1.38 (0.98-1.83)		156	13.5 (11.2-16.2)	
Q3 (2.06-2.72)	157	3.15 (1.92-4.74)		157	9.67 (5.75-19.6)		156	1.38 (0.96-1.76)		157	12.3 (10.4-15.0)	
Q4 (2.73-5.50)	156	3.30 (1.79-6.02)	0.84	156	10.4 (4.84-19.6)	0.24	154	1.23 (0.92-1.61)	0.002	154	12.0 (10.3-14.8)	0.002
Flavonols (mg/1,000 kcal)												
Q1 (1.14-6.07)	157	3.12 (2.01-4.68)		157	9.71 (4.70-16.3)		156	1.47 (1.12-1.96)		156	13.5 (11.1-15.8)	
Q2 (6.08-8.63)	156	3.22 (1.97-5.32)		156	8.83 (3.86-19.1)		155	1.35 (0.97-1.79)		156	13.3 (11.5-16.2)	
Q3 (8.64-12.4)	157	2.85 (1.57-4.60)		157	8.72 (4.29-19.0)		157	1.41 (1.04-1.78)		157	13.0 (10.9-15.7)	
Q4 (12.5-28.5)	156	3.32 (2.06-6.04)	0.36	156	9.01 (5.11-17.3)	0.11	154	1.21 (0.89-1.53)	0.0007	155	12.1 (10.2-14.6)	0.006
Dry beans (g/1,000 kcal)												
Q1 (0-1.56)	157	2.99 (1.99-4.65)		157	9.38 (4.69-15.9)		156	1.40 (0.97-1.91)		157	13.7 (11.3-16.0)	
Q2 (1.57-3.77)	156	3.33 (1.96-5.22)		156	9.34 (4.43-18.6)		155	1.39 (0.96-1.82)		155	13.2 (11.0-16.2)	
Q3 (3.78-7.90)	157	3.24 (1.84-4.93)		157	9.38 (5.18-18.9)		156	1.37 (1.08-1.73)		157	12.5 (10.8-14.9)	
Q4 (7.91-58.5)	156	3.13 (2.03-5.82)	0.33	156	8.38 (4.11-17.3)	0.35	155	1.25 (0.97-1.76)	0.49	155	13.0 (10.3-15.3)	0.03

Abbreviation: IQR, interquartile range.

\**P* values for differences in medians were calculated using Wilcoxon rank-sum test (two-group comparison) and Kruskal-Wallis test (comparison of more than two groups). *P* values for trend of dietary intake characteristics were calculated using a multiple regression model adjusting for the baseline characteristics of age (in quartiles: <56, 56-63, 64-69, >69 y), sex, BMI (<25, 25.0-29.9, ≥30 kg/m<sup>2</sup>), and regular NSAID use.

†Physical activity was defined as self-reported time typically spent for any type of moderate or vigorous physical activity in hours per week.

‡Regular NSAID use was defined as taking medication ≥1 monthly.

NIH serum sample, as standard curves for adiponectin were consistent and CVs within day and within plates were below 20%.

### Statistical analysis

Baseline and T1 characteristics (T1 was the time of serum collection) by adenoma recurrence at T4 were evaluated using Wilcoxon rank-sum test for continuous variables and Fisher's exact test for categorical variables and are shown as medians and interquartile ranges. The associations between serum indicators (continuous) and dietary exposures (in energy-adjusted quartiles using the nutrient density method), as well as sex, age quartiles, body mass index (BMI; <25, 25.0-29.9,  $\geq$ 30 kg/m<sup>2</sup>), physical activity (hours per week of moderate and vigorous exercise) quartiles, race, and regular nonsteroidal anti-inflammatory drug (NSAID) use at T1, were evaluated using Spearman correlation coefficients, Kruskal-Wallis tests, and multiple linear regression models. We selected the five dietary exposure indicators (percent fat from calories, fiber, fruits and vegetables, flavonols, and dry beans) proposed to decrease (alone or in combination) the risk of adenoma recurrence in the PPT (37-39).

The association between serum indicators at T1 and adenoma recurrence at T4 (no polyp versus any, multiple, high-risk, or advanced adenoma) was estimated by logistic regression calculation of odds ratios (OR) and 95% confidence intervals (95% CI), using the lowest quartile of serum analyte concentration as the reference category. Linear trend testing was carried out using median values from the quartiles of the serum biomarker concentrations. Tertiles of serum concentrations were used when investigating the association between each of the four analytes and advanced adenoma recurrence because of the small number of advanced cases.

For all logistic and multiple regression models, potential confounders (listed in Table 1) were added to the models in a stepwise fashion; if a variable changed the association by >10%, was associated with both study variables, and had a  $\chi^2$  *P* value  $\leq$  0.20, it remained in the model. Logistic regression models were adjusted for sex, age quartiles, BMI (<25, 25.0-29.9,  $\geq$ 30 kg/m<sup>2</sup>), and regular NSAID use, defined as at least once-monthly usage on the baseline questionnaire. Analyses were stratified by sex, BMI (<25, 25.0-29.9,  $\geq$ 30 kg/m<sup>2</sup> at T1), and physical activity tertiles (at T1). All *P* values correspond to two-sided tests. Statistical tests were considered to be statistically significant when *P*  $\leq$  0.05.

## Results

At the end of the 4-year trial, 44.2% of participants had no polyps, 38.6% had  $\geq$ 1 adenoma, 16.3% had multiple adenomas, 10.8% had high-risk adenoma, and 5.3% had  $\geq$ 1 advanced adenoma (Table 1). Adenoma recurrence was more common in men, but less common in users of supplements and in women who used hormone therapy (Table 1). Furthermore, individuals with multiple,

high-risk, or advanced adenoma recurrence were older than those without polyps (Table 1).

Statistically significant but weak correlations were observed for serum concentrations of C-peptide with adiponectin ( $r_{\text{Spearman}} = -0.16$ ), homocysteine ( $r = 0.24$ ), and leptin ( $r = 0.25$ ), and between leptin and homocysteine ( $r = -0.16$ ). The serum concentrations of adiponectin and leptin at T1 were highly correlated with those at T4 ( $r = 0.68$  and  $r = 0.82$ ; respectively). On average, females had higher serum concentrations of adiponectin and leptin and lower concentrations of C-peptide and homocysteine (Table 2). With regard to race, Caucasians had higher concentrations of adiponectin. There was a curvilinear relationship between the four serum indicators and age, with lower concentrations in the first quartile (36-56 years old) and similar concentrations in the other three quartiles (57-87 years old); the relationship was only statistically significant in males (data not shown). BMI was positively associated with serum leptin ( $r = 0.38$ ) and C-peptide ( $r = 0.39$ ) and weakly correlated with homocysteine ( $r = 0.11$ ); furthermore, physical activity was mildly inversely related to leptin ( $r = -0.25$ ) and C-peptide ( $r = -0.15$ ).

Those in the highest, versus the lowest, intake quartile of fiber, fruits and vegetables, and flavonols had lower serum concentrations of C-peptide (Table 2: 1.27 versus 1.44 ng/mL for fiber; 1.23 versus 1.45 ng/mL for fruits and vegetables; 1.21 versus 1.47 ng/mL for flavonols) and homocysteine (12.6 versus 13.9  $\mu$ mol/L for fiber; 12.0 versus 13.9  $\mu$ mol/L for fruits and vegetables; 12.1 versus 13.4  $\mu$ mol/L for flavonols), whereas percent calories from fat were positively associated with C-peptide (1.44 versus 1.26 ng/mL) and homocysteine (13.5 versus 12.7  $\mu$ mol/L; Table 2). Serum homocysteine concentrations were weakly inversely correlated with folate consumption from foods ( $r = -0.14$ ) and from supplements ( $r = -0.23$ ). Multivariate regression models of serum indicators by dietary exposure were not mutually adjusted for all dietary variables (percent calories from fat, fiber, fruits and vegetables, flavonols, and dry beans) because of the high correlations among them, especially between fiber and fruits and vegetables ( $r = 0.76$ ), fiber and fat ( $r = -0.59$ ), and flavonols and dry beans ( $r = 0.62$ ).

Individuals without polyp recurrence after 4 years had the highest leptin and the lowest homocysteine concentrations in serum (Table 3). For homocysteine, higher concentrations were observed with increasing adenoma number and more advanced adenoma type, whereas no gradual differences were found for leptin.

Although there was no association for adiponectin or C-peptide and adenoma recurrence (Table 4), we observed a statistically significant inverse association between serum leptin concentrations and advanced adenoma recurrence (3rd versus 1st tertile: OR, 0.22; 95% CI, 0.06-0.79). High homocysteine concentrations were positively associated with any (4th versus 1st quartile: OR, 2.21; 95% CI, 1.27-3.86) and multiple adenoma recurrence (OR, 2.11; 95% CI, 1.01-4.40), and there was a suggestive

**Table 3.** Medians (interquartile ranges) of serum adiponectin, leptin, C-peptide, and homocysteine concentrations at T1 in the control arm of the PPT, by adenoma recurrence at T4

Outcome	<i>n</i>	Adiponectin (ng/mL)	<i>P</i> *	<i>n</i>	Leptin (ng/mL)	<i>P</i> *	<i>n</i>	C-peptide (ng/mL)	<i>P</i> *	<i>n</i>	Homocysteine (μmol/L)	<i>P</i> *
		Median (IQR)			Median (IQR)			Median (IQR)			Median (IQR)	
Total	627	3.16 (1.94-5.10)		627	9.31 (4.63-17.4)		623	1.37 (0.98-1.80)		625	13.0 (10.8-15.7)	
No polyp	277	3.29 (2.03-5.56)		277	10.5 (5.89-20.7)		274	1.34 (0.96-1.80)		276	12.5 (10.5-14.7)	
Nonadenomatous polyps only	108	2.97 (1.60-5.21)	0.29	108	7.22 (3.55-19.6)	0.06	107	1.32 (0.92-1.69)	0.80	107	13.4 (10.8-16.4)	0.02
Any adenoma	242	3.08 (1.82-4.74)	0.15	242	7.79 (4.30-13.9)	0.0008	242	1.42 (1.05-1.88)	0.06	242	13.7 (11.2-16.3)	0.0004
One adenoma	140	3.14 (1.88-4.60)	0.33	140	4.68 (4.29-13.2)	0.002	140	1.41 (1.00-1.85)	0.26	140	13.6 (11.1-16.3)	0.006
Multiple adenoma	102	2.98 (1.80-4.80)	0.17	102	8.16 (4.35-14.0)	0.03	102	1.45 (1.15-1.97)	0.05	102	13.8 (11.4-16.1)	0.003
Low-risk adenoma	174	3.14 (1.78-4.84)	0.26	174	7.76 (4.49-14.2)	0.004	174	1.39 (1.03-1.80)	0.34	174	13.6 (11.1-16.3)	0.004
High-risk adenoma	68	3.03 (1.98-4.60)	0.21	68	7.92 (3.86-13.3)	0.02	68	1.52 (1.16-2.00)	0.01	68	14.4 (11.6-16.2)	0.003
Nonadvanced adenoma	209	3.10 (1.80-4.80)	0.22	209	8.15 (4.35-14.1)	0.002	209	1.41 (1.08-1.83)	0.09	209	13.7 (11.4-16.2)	0.0007
Advanced adenoma	33	3.03 (2.01-4.03)	0.25	33	7.34 (3.87-12.9)	0.04	33	1.46 (0.99-2.03)	0.24	33	14.2 (11.1-16.6)	0.07

NOTE: Advanced adenoma is defined as  $\geq 1$  adenoma of  $\geq 1$  cm in size, having  $\geq 25\%$  villous component, or exhibiting high-grade dysplasia. High-risk adenoma is defined as  $\geq 1$  advanced adenoma or  $\geq 3$  adenomas; in contrast, low-risk adenoma is defined as 1 or 2 adenomas and no advanced adenoma.

\*All comparisons against the no-polyp group using Wilcoxon rank-sum test.

**Table 4.** Association between serum adiponectin, leptin, C-peptide, and homocysteine at T1 and adenoma recurrence at T4 (*n* = 519)

Metabolic indicator quartiles	Control, <i>n</i> (%)	Case, <i>n</i> (%)	Any adenoma, OR (95% CI)*	Case, <i>n</i> (%)	Multiple adenoma, OR (95% CI)*	Case, <i>n</i> (%)	High-risk adenoma, OR (95% CI)*	Metabolic indicator tertiles†	Control, <i>n</i> (%)	Case, <i>n</i> (%)	Advanced adenoma, OR (95% CI)*
Adiponectin (ng/mL)											
Q1 (0.08-1.94)	62 (39.5)	66 (42.0)	1‡	30 (19.1)	1‡	15 (9.6)	1‡	Q1 (0.08-2.41)	82 (39.2)	11 (5.3)	1‡
Q2 (1.95-3.16)	69 (43.9)	59 (37.6)	0.86 (0.52-1.43)	24 (15.3)	0.73 (0.38-1.41)	22 (14.0)	1.38 (0.64-3.00)	Q2 (2.42-4.40)	98 (46.7)	14 (6.7)	1.20 (0.50-2.89)
Q3 (3.17-5.10)	67 (42.7)	68 (43.3)	1.03 (0.63-1.70)	26 (16.6)	0.88 (0.45-1.70)	21 (13.4)	1.46 (0.66-3.22)	Q3 (4.41-17.4)	97 (46.6)	8 (3.8)	0.61 (0.22-1.70)
Q4 (5.11-17.4)	79 (50.6)	49 (31.4)	0.69 (0.41-1.17)	22 (14.1)	0.67 (0.34-1.33)	10 (6.4)	0.64 (0.25-1.61)				
<i>P</i> <sub>trend</sub>			0.22		0.34		0.30				0.30
Leptin (ng/mL)											
Q1 (0.63-4.64)	55 (35.0)	66 (42.0)	1‡	29 (18.5)	1‡	20 (12.7)	1‡	Q1 (0.63-6.06)	72 (34.4)	14 (6.7)	1‡
Q2 (4.65-9.31)	66 (42.0)	68 (43.3)	0.87 (0.52-1.47)	24 (15.3)	0.79 (0.40-1.58)	16 (10.2)	0.78 (0.35-1.73)	Q2 (6.07-13.9)	94 (44.8)	14 (6.7)	0.66 (0.27-1.61)
Q3 (9.32-17.3)	73 (46.5)	63 (40.1)	0.80 (0.46-1.38)	28 (17.8)	0.78 (0.38-1.59)	21 (13.4)	0.92 (0.41-2.07)	Q3 (14.0-185)	111 (53.4)	5 (2.4)	0.22 (0.06-0.79)
Q4 (17.4-185)	83 (53.2)	45 (28.8)	0.64 (0.32-1.28)	21 (13.5)	0.69 (0.29-1.67)	11 (7.1)	0.58 (0.20-1.64)				
<i>P</i> <sub>trend</sub>			0.22		0.50		0.34				0.02
C-peptide (ng/mL)											
Q1 (0.13-0.98)	74 (47.4)	52 (33.3)	1‡	18 (11.5)	1‡	11 (7.1)	1‡	Q1 (0.13-1.13)	104 (49.5)	10 (4.8)	1‡
Q2 (0.99-1.37)	77 (48.4)	56 (35.2)	0.95 (0.56-1.59)	26 (16.4)	1.20 (0.59-2.44)	24 (8.8)	1.07 (0.44-2.62)	Q2 (1.14-1.63)	81 (39.3)	9 (4.4)	0.98 (0.36-2.66)
Q3 (1.38-1.80)	57 (37.0)	67 (43.5)	1.48 (0.86-2.56)	28 (18.2)	1.65 (0.78-3.49)	19 (12.3)	1.91 (0.79-4.66)	Q3 (1.64-4.50)	57 (37.0)	14 (6.8)	1.44 (0.53-3.88)
Q4 (1.81-4.50)	66 (42.9)	67 (43.5)	1.14 (0.66-1.99)	30 (19.5)	1.33 (0.62-2.85)	24 (15.6)	1.79 (0.74-4.34)				
<i>P</i> <sub>trend</sub>			0.48		0.46		0.14				0.45
Homocysteine (μmol/L)											
Q1 (4.78-10.8)	81 (51.3)	49 (31.0)	1‡	19 (12.0)	1‡	12 (7.6)	1‡	Q1 (4.78-11.5)	103 (49.3)	11 (5.3)	1‡
Q2 (10.8-13.0)	78 (49.7)	58 (36.9)	1.02 (0.61-1.71)	25 (15.9)	1.06 (0.52-2.15)	18 (11.5)	1.16 (0.50-2.69)	Q2 (11.6-14.7)	106 (50.7)	6 (2.9)	0.40 (0.14-1.16)
Q3 (13.1-15.6)	73 (46.8)	58 (37.2)	1.04 (0.61-1.77)	26 (16.7)	1.06 (0.51-2.18)	16 (10.3)	1.00 (0.42-2.40)	Q3 (14.8-79.8)	67 (32.4)	16 (7.7)	1.66 (0.67-4.16)
Q4 (15.7-79.8)	44 (28.6)	77 (50.0)	2.21 (1.27-3.86)	32 (20.8)	2.11 (1.01-4.40)	22 (14.3)	2.11 (0.89-4.97)				
<i>P</i> <sub>trend</sub>			0.003		0.03		0.08				0.16

NOTE: Of the 627 participants, 108 with nonadenomatous polyps only were excluded from the analysis. Advanced adenoma is defined as  $\geq 1$  adenoma of  $\geq 1$  cm in size, having  $\geq 25\%$  villous component, or exhibiting high-grade dysplasia. High-risk adenoma is defined as  $\geq 1$  advanced adenoma or  $\geq 3$  adenomas.

\*All comparisons against the no-polyp group (control). Multivariate OR and 95% CI models were adjusted for the baseline characteristics of age (in quartiles: <56, 56-63, 64-69, >69 y), sex, BMI (<25, 25.0-29.9,  $\geq 30$  kg/m<sup>2</sup>), and regular NSAID use. Regular NSAID use was defined as taking medication  $\geq 1$  monthly.

†Tertiles used for advanced adenoma due to small number.

‡Reference category.



positive association between high homocysteine concentrations and high-risk adenoma recurrence (OR, 2.11; 95% CI, 0.89-4.97; Table 4).

Mutually adjusting multivariate regression models of adenoma recurrence by serum indicators or using the covariates reported at T1 (rather than baseline) did not substantially change the risk estimates (results not shown). The association between leptin and advanced adenoma recurrence (OR, 0.27; 95% CI, 0.07-0.98;  $P_{\text{trend}} = 0.04$ ) and that between homocysteine and any adenoma recurrence were attenuated but remained statistically significant (OR, 1.67; 95% CI, 1.02-2.75;  $P_{\text{trend}} = 0.04$ ) when the reference group was no adenoma recurrence, as opposed to when the "no polyp" group was used for the main analyses.

There was no interaction between BMI or physical activity and serum adiponectin, leptin, C-peptide, or homocysteine concentrations and adenoma recurrence. Although there was no interaction between sex and adiponectin, C-peptide, or homocysteine, there was an interaction between sex and leptin ( $P_{\text{interaction}} = 0.01$  for any adenoma;  $P_{\text{interaction}} = 0.06$  for multiple adenoma). In males, we observed a nonsignificant inverse association between serum leptin concentration and any (4th versus 1st gender specific quartile: OR, 0.53; 95% CI, 0.25-1.12;  $P_{\text{trend}} = 0.03$ ) and multiple adenoma recurrence (OR, 0.42; 95% CI, 0.17-1.08;  $P_{\text{trend}} = 0.08$ ). In contrast, leptin concentrations in females had a nonsignificant positive association with any (OR, 1.44; 95% CI, 0.52-4.02;  $P_{\text{trend}} = 0.27$ ) and multiple adenoma recurrence (OR, 3.16; 95% CI, 0.74-13.6;  $P_{\text{trend}} = 0.06$ ).

An increase in serum leptin concentrations from T1 to T4 was associated with a statistically significantly increased risk of any (4th versus 1st quartile: OR, 1.74; 95% CI, 1.04-2.93;  $P_{\text{trend}} = 0.03$ ) and multiple adenoma recurrence (OR, 2.19; 95% CI, 1.08-4.44;  $P_{\text{trend}} = 0.04$ ), which was not modified by sex (results not shown). In males, an increase in leptin concentration was positively significant associated with any (OR, 2.71; 95% CI, 1.41-5.22;  $P_{\text{trend}} = 0.008$ ) and multiple adenoma recurrence (OR, 3.54; 95% CI, 1.36-9.22;  $P_{\text{trend}} = 0.03$ ); the same trend was observed in women, but it did not reach statistical significance (OR<sub>any recurrence</sub> = 1.77; 95% CI, 0.72-4.31;  $P_{\text{trend}} = 0.26$ ; OR<sub>multiple recurrence</sub> = 1.72; 95% CI, 0.55-5.37;  $P_{\text{trend}} = 0.48$ ; results not shown). We found no association for change in adiponectin concentration between T1 and T4.

## Discussion

Our objective was to investigate whether adiponectin, leptin, C-peptide, or homocysteine was associated with early stages of colorectal carcinogenesis or could be modified by diet. Elevated homocysteine concentrations were associated with an approximately 2-fold increased risk of recurrence of any, multiple, and high-risk adenoma at the end of the 4-year trial. A diet low in fat and rich in fiber, fruits and vegetables, and flavonols was associated with lower serum concentrations of C-peptide and homocysteine. The data suggest that elevated serum homocysteine

concentrations may serve as an indicator for dietary exposure and early stages of colorectal carcinogenesis.

Similar to our observations, a positive association between circulating homocysteine and colorectal adenoma (32) or adenoma recurrence (33), as well as lower homocysteine concentrations in individuals with hyperplastic polyps than in individuals with adenomas (44), has been reported. The limited sample size (35-40 cases) of some previous studies may partly explain the inconsistency in the literature about the association between homocysteine and risk of colorectal adenoma (34-36). A plausible role for homocysteine in indicating early neoplastic changes has been reported in *in vitro* mechanistic studies. Elevated homocysteine may promote carcinogenesis through NF- $\kappa$ B activation, which induces the expression of proinflammatory cytokines and cancer-promoting genes, and through formation of reactive oxygen species from its highly reactive thiol group (31). Elevated homocysteine concentrations may also indicate altered DNA synthesis and methylation patterns because homocysteine concentrations are associated with cobalamin, riboflavin, and folate status and mutations in enzymes involved in one-carbon metabolism (30, 31). In a previous analysis in the PPT, we found no association between total and dietary folate and adenoma recurrence (45). Given that homocysteine has been inversely associated with dietary folate and folate supplements (46-48) and positively associated with colorectal adenoma recurrence (33) in this and other studies, circulating homocysteine concentrations may predict or mediate a chemopreventive response to folate supplementation.

Previously published studies have reported elevated serum leptin concentrations for colorectal adenoma (15) and cancer (16-18), particularly in men (15, 18), as well as decreased concentrations for colorectal adenoma (8) and even lower concentrations for colorectal cancer (8, 19-21). Our study found a decreased risk of any adenoma recurrence in men and advanced adenoma recurrence overall for those with higher leptin concentrations. The inconsistency in the literature may be a result of the small sample size used in some previous studies (all studies, except for a Norwegian and a Swedish study, had less than 80 cases), the tumor stage at blood draw, the proportion of males to females (15, 18), or confounding by BMI [results were either not adjusted (8, 19-21) or the effect was attenuated after BMI adjustment (ref. 15)], although BMI did not confound the association between leptin and adenoma recurrence in our study. Studies in cell culture suggest that leptin may activate signal transduction pathways involved in carcinogenesis (6), although animal models using exogenous leptin do not confirm that leptin is a molecular target for early stages of colorectal carcinogenesis (49-51). In humans, increased expression of leptin in colorectal tumor tissue is positively associated with advanced tumor stage and increased disease-free survival (52-55), suggesting that leptin plays a role in colorectal carcinogenesis. Serum leptin concentrations, however, have not been associated with expression of leptin and

its receptor in colorectal tumor tissue (53). Our observation that the change in leptin concentrations from T1 to T4 is positively associated with adenoma recurrence is intriguing and consistent with the increase in leptin expression with tumor stage. In summary, our results for leptin as an indicator for the early stages of colorectal carcinogenesis are inconclusive. Further investigations are needed to evaluate whether changes in serum leptin concentrations over time, rather than serum leptin concentrations at a single time point, may be an indicator of adenoma recurrence.

We did not observe an association between serum adiponectin concentration and adenoma recurrence. Similarly, no association between adiponectin and colorectal adenoma was observed in the Japanese Self Defense Forces Health Study (13). However, three other studies revealed an inverse association between adiponectin and colorectal adenoma (8-10), which was even stronger between adiponectin and colorectal cancer (8, 10). In addition, we observed lower adiponectin concentrations with advanced stage of colorectal adenoma. Both findings suggest that adiponectin concentrations may be a better risk indicator for more advanced stages of colorectal neoplasms. Reasons for the inconsistencies in the literature for adiponectin are not clear. Adiponectin receptors are expressed in normal and colorectal cancer tissues in humans (56). In cell culture, adiponectin inhibits colorectal carcinogenesis (57), but this has not been conclusively confirmed in transgenic animal models with elevated adiponectin concentrations (58, 59).

Our study found that C-peptide was inversely associated with a healthy diet—low in fat and rich in fiber, flavonols, and fruits and vegetables—but not with colorectal adenoma recurrence. Most previous studies have failed to find an association between colorectal adenoma and C-peptide (27, 28). In contrast, several studies have observed a positive association between C-peptide and colorectal cancer (23-25). Our observation of a marginal increase in C-peptide concentrations with advancing stage of colorectal adenoma may suggest that elevated C-peptide concentrations are a better indicator of risk for colorectal cancer than for colorectal adenoma.

A major strength of our study was the detailed adenoma data available from complete colonoscopies performed at baseline, year 1, and year 4, as well as histologic characteristics noted by two pathologists independently, decreasing the risk of misclassification. Other strengths

of this study included the prospective collection of both serum and dietary data, as well as the use of a questionnaire that was developed specifically for this study to focus on fiber and fruit and vegetable consumption (41) and linked to the recently released and validated U.S. Department of Agriculture flavonoid database (42). Furthermore, the dietary questionnaire was reviewed by registered dietitians, which further improved its accuracy (43).

There are, however, several limitations to our study. Our study findings may not apply to the general population because all participants had a history of adenomas and a relatively healthy diet and most engaged in a health-promoting lifestyle. Because all analyzed samples were from participants in the control arm of an intervention study, potential conclusions about the effect of a low-fat, high-fiber, and high-fruit and vegetable dietary intervention on serum homocysteine and leptin concentrations are limited and warrant further investigation. Measurement error related to the dietary assessment techniques could be present and could lead to attenuated risk estimates. Furthermore, the serum analyses were associated with relatively high CVs, especially for adiponectin. Future studies are warranted to better understand and decrease the variation using the current adiponectin antibody.

In conclusion, our results suggest that high serum homocysteine concentrations may indicate increased risk of colorectal adenoma recurrence and correlate with an “unhealthy” diet that is high in fat and low in fiber, fruits and vegetables, and flavonols. Verification of these results in prospective cohorts with high-quality dietary and serum homocysteine measures is needed to clarify the role of serum homocysteine concentrations for dietary cancer prevention.

### Disclosure of Potential Conflicts of Interest

The authors have no conflicts of interest to declare.

### Grant Support

Intramural Research Program, National Cancer Institute, NIH, DHHS (Bethesda, MD).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 10/15/2009; revised 03/19/2010; accepted 03/24/2010; published OnlineFirst 05/25/2010.

### References

- Giovannucci E, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk of colorectal adenoma in women (United States). *Cancer Causes Control* 1996;7:253-63.
- IARC. Weight control and physical activity. Vol. 6. Lyon (France): IARC Press; 2002.
- World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity and the prevention of cancer: a global perspective. Washington (DC): AICR; 2007.
- Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. *Br J Cancer* 2006;94:1221-5.
- Housa D, Housova J, Vernerova Z, Haluzik M. Adipocytokines and cancer. *Physiol Res* 2006;55:233-44.
- Hursting SD, Lashinger LM, Wheatley KW, et al. Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link. *Best Pract Res Clin Endocrinol Metab* 2008; 22:659-69.
- Gunter MJ, Leitzmann MF. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. *J Nutr Biochem* 2006;17: 145-56.
- Kumor A, Daniel P, Pietruczuk M, Malecka-Panas E. Serum leptin,

- adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. *Int J Colorectal Dis* 2009;24:275–81.
9. Otake S, Takeda H, Suzuki Y, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. *Clin Cancer Res* 2005;11:3642–6.
  10. Erarslan E, Turkay C, Koktener A, Koca C, Uz B, Bavbek N. Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia. *Dig Dis Sci* 2009;54:862–8.
  11. Ferroni P, Palmirotta R, Spila A, et al. Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. *Anticancer Res* 2007;27:483–9.
  12. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. *J Natl Cancer Inst* 2005;97:1688–94.
  13. Fukumoto J, Otake T, Tajima O, et al. Adiponectin and colorectal adenomas: Self Defense Forces Health Study. *Cancer Sci* 2008;99:781–6.
  14. Lukanova A, Soderberg S, Kaaks R, Jellum E, Stattin P. Serum adiponectin is not associated with risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 2006;15:401–2.
  15. Chia VM, Newcomb PA, Lampe JW, et al. Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. *Cancer Epidemiol Biomarkers Prev* 2007;16:2697–703.
  16. Tamakoshi K, Toyoshima H, Wakai K, et al. Leptin is associated with an increased female colorectal cancer risk: a nested case-control study in Japan. *Oncology* 2005;68:454–61.
  17. Stattin P, Lukanova A, Biessy C, et al. Obesity and colon cancer: does leptin provide a link? *Int J Cancer* 2004;109:149–52.
  18. Stattin P, Palmqvist R, Soderberg S, et al. Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. *Oncol Rep* 2003;10:2015–21.
  19. Wallace AM, Sattar N, McMillan DC. Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients. *Clin Cancer Res* 1998;4:2977–9.
  20. Bolukbas FF, Kilic H, Bolukbas C, et al. Serum leptin concentration and advanced gastrointestinal cancers: a case controlled study. *BMC Cancer* 2004;4:29.
  21. Arpacı F, Yilmaz Mİ, Ozet A, et al. Low serum leptin level in colon cancer patients without significant weight loss. *Tumori* 2002;88:147–9.
  22. Hovorka R, Jones RH. How to measure insulin secretion. *Diabetes Metab Rev* 1994;10:91–117.
  23. Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. *J Natl Cancer Inst* 2000;92:1592–600.
  24. Ma J, Giovannucci E, Pollak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. *J Natl Cancer Inst* 2004;96:546–53.
  25. Jenab M, Riboli E, Cleveland RJ, et al. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer* 2007;121:368–76.
  26. Wei EK, Ma J, Pollak MN, et al. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. *Cancer Epidemiol Biomarkers Prev* 2006;15:750–5.
  27. Tsilidis KK, Brancati FL, Pollak MN, et al. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. *Cancer Causes Control* 21:1–10.
  28. Kaczka A, Kumor A, Pietruczuk M, Malecka-Panas E. Serum concentration of insulin, C-peptide and insulin-like growth factor I in patients with colon adenomas and colorectal cancer. *Pol Merkur Lekarski* 2007;22:373–5.
  29. Meigs JB, Jacques PF, Selhub J, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. *Diabetes Care* 2001;24:1403–10.
  30. Lucock MD. Synergy of genes and nutrients: the case of homocysteine. *Curr Opin Clin Nutr Metab Care* 2006;9:748–56.
  31. Zhou J, Austin RC. Contributions of hyperhomocysteinemia to atherosclerosis: causal relationship and potential mechanisms. *Biofactors* 2009;35:120–9.
  32. Powers HJ, Hill MH, Welfare M, et al. Responses of biomarkers of folate and riboflavin status to folate and riboflavin supplementation in healthy and colorectal polyp patients (the FAB2 Study). *Cancer Epidemiol Biomarkers Prev* 2007;16:2128–35.
  33. Martinez ME, Giovannucci E, Jiang R, et al. Folate fortification, plasma folate, homocysteine and colorectal adenoma recurrence. *Int J Cancer* 2006;119:1440–6.
  34. Hwang NC, Kim YH, Shim SG, et al. Is serum homocysteine level elevated in colorectal tumor? *Korean J Gastroenterol* 2005;45:97–102.
  35. Al-Ghnam R, Peters J, Foresti R, Heaton N, Pufulete M. Methylation of estrogen receptor  $\alpha$  and mutL homolog 1 in normal colonic mucosa: association with folate and vitamin B-12 status in subjects with and without colorectal neoplasia. *Am J Clin Nutr* 2007;86:1064–72.
  36. Ashktorab H, Begum R, Akhgar A, et al. Folate status and risk of colorectal polyps in African Americans. *Dig Dis Sci* 2007;52:1462–70.
  37. Lanza E, Hartman TJ, Albert PS, et al. High dry bean intake and reduced risk of advanced colorectal adenoma recurrence among participants in the Polyp Prevention Trial. *J Nutr* 2006;136:1896–903.
  38. Bobe G, Sansbury LB, Albert PS, et al. Dietary flavonoids and colorectal adenoma recurrence in the Polyp Prevention Trial. *Cancer Epidemiol Biomarkers Prev* 2008;17:1344–53.
  39. Sansbury LB, Wanke K, Albert PS, Kahle L, Schatzkin A, Lanza E. The effect of strict adherence to a high-fiber, high-fruit and -vegetable, and low-fat eating pattern on adenoma recurrence. *Am J Epidemiol* 2009;170:576–84.
  40. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. *Polyp Prevention Trial Study Group. N Engl J Med* 2000;342:1149–55.
  41. Lanza E, Schatzkin A, Daston C, et al. Implementation of a 4-y, high-fiber, high-fruit-and-vegetable, low-fat dietary intervention: results of dietary changes in the Polyp Prevention Trial. *Am J Clin Nutr* 2001;74:387–401.
  42. U.S. Department of Agriculture. USDA database for the flavonoid content of selected foods. c2007 [cited 2010 April 7]. Available from: <http://www.nal.usda.gov/fnic/foodcomp/Data/Flav/Flav02.pdf> 2007.
  43. Caan BJ, Lanza E, Schatzkin A, et al. Does nutritionist review of a self-administered food frequency questionnaire improve data quality? *Public Health Nutr* 1999;2:565–9.
  44. Kim YI, Fawaz K, Knox T, et al. Colonic mucosal concentrations of folate correlate well with blood measurements of folate status in persons with colorectal polyps. *Am J Clin Nutr* 1998;68:866–72.
  45. Murphy G, Sansbury LB, Cross AJ, et al. Folate and MTHFR: risk of adenoma recurrence in the Polyp Prevention Trial. *Cancer Causes Control* 2008;19:751–8.
  46. Martinez ME, Henning SM, Alberts DS. Folate and colorectal neoplasia: relation between plasma and dietary markers of folate and adenoma recurrence. *Am J Clin Nutr* 2004;79:691–7.
  47. van den Donk M, Pellis L, Crott JW, et al. Folic acid and vitamin B-12 supplementation does not favorably influence uracil incorporation and promoter methylation in rectal mucosa DNA of subjects with previous colorectal adenomas. *J Nutr* 2007;137:2114–20.
  48. Hazra A, Selhub J, Chao WH, Ueland PM, Hunter DJ, Baron JA. Uracil misincorporation into DNA and folic acid supplementation. *Am J Clin Nutr* 91:160–5.
  49. Aparicio T, Guilmeau S, Giot H, et al. Leptin reduces the development of the initial precancerous lesions induced by azoxymethane in the rat colonic mucosa. *Gastroenterology* 2004;126:499–510.
  50. Aparicio T, Kotelevets L, Tsocas A, et al. Leptin stimulates the proliferation of human colon cancer cells *in vitro* but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in Apc(Min/+) mice. *Gut* 2005;54:1136–45.
  51. FitzGerald AJ, Mandir N, Goodlad RA. Leptin, cell proliferation and crypt fission in the gastrointestinal tract of intravenously fed rats. *Cell Prolif* 2005;38:25–33.

52. Koda M, Sulkowska M, Kanczuga-Koda L, Surmacz E, Sulkowski S. Overexpression of the obesity hormone leptin in human colorectal cancer. *J Clin Pathol* 2007;60:902–6.
53. Aloulou N, Bastuji-Garin S, Le Gouvello S, et al. Involvement of the leptin receptor in the immune response in intestinal cancer. *Cancer Res* 2008;68:9413–22.
54. Paik SS, Jang SM, Jang KS, Lee KH, Choi D, Jang SJ. Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. *Ann Surg Oncol* 2009;16:297–303.
55. Uddin S, Bavi PP, Hussain AR, et al. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. *Carcinogenesis* 2009;30:1832–40.
56. Yoneda K, Tomimoto A, Endo H, et al. Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue. *Oncol Rep* 2008;20:479–83.
57. Fenton JI, Birmingham JM, Hursting SD, Hord NG. Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in *Apc Min/+* colon epithelial cells. *Int J Cancer* 2008;122:2437–45.
58. Fujisawa T, Endo H, Tomimoto A, et al. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. *Gut* 2008;57:1531–8.
59. Ealey KN, Archer MC. Elevated circulating adiponectin and elevated insulin sensitivity in adiponectin transgenic mice are not associated with reduced susceptibility to colon carcinogenesis. *Int J Cancer* 2009;124:2226–30.

# BLOOD CANCER DISCOVERY

## Serum Adiponectin, Leptin, C-Peptide, Homocysteine, and Colorectal Adenoma Recurrence in the Polyp Prevention Trial

Gerd Bobe, Gwen Murphy, Connie J. Rogers, et al.

*Cancer Epidemiol Biomarkers Prev* 2010;19:1441-1452. Published OnlineFirst May 25, 2010.

**Updated version** Access the most recent version of this article at:  
doi: [10.1158/1055-9965.EPI-09-1082](https://doi.org/10.1158/1055-9965.EPI-09-1082)

**Cited articles** This article cites 54 articles, 19 of which you can access for free at:  
<http://cebp.aacrjournals.org/content/19/6/1441.full#ref-list-1>

**Citing articles** This article has been cited by 2 HighWire-hosted articles. Access the articles at:  
<http://cebp.aacrjournals.org/content/19/6/1441.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cebp.aacrjournals.org/content/19/6/1441>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.